Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867255 · ClinicalTrials.gov registry record · Phase 1
Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01867255: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01867255 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01867255, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether a significant and predictable change in bioavailability of extended-release venlafaxine occurs following Roux-en-Y gastric bypass.
Interventions
- DRUG venlafaxine ER (extended-release) 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867255
The ClinicalTrials.gov registry entry for NCT01867255 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which venlafaxine ER (extended-release) 75 mg is the first listed.
NCT01867255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01867255 about?
NCT01867255 is a clinical study titled "Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels". The purpose of the study is to determine whether a significant and predictable change in bioavailability of extended-release venlafaxine occurs following Roux-en-Y gastric bypass.
What is the current status of trial NCT01867255?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01867255?
The interventions under investigation include: venlafaxine ER (extended-release) 75 mg (DRUG).
Who is sponsoring clinical trial NCT01867255?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.